Gsk (GSK) Retained Earnings (2009 - 2026)

Gsk (GSK) has 18 years of Retained Earnings data on file, last reported at $15.4 billion in Q2 2026.

• For the quarter ending Q2 2026, Retained Earnings rose 31.06% year-over-year to $15.4 billion; the trailing twelve-month figure through Jun 2026 stood at $15.4 billion (up 31.06% YoY), and the FY2025 full-year result was $13.6 billion, up 36.27% from the prior year.
• Retained Earnings was $15.4 billion for Q2 2026 at Gsk, down from $15.6 billion in the prior quarter.
• In the past five years, Retained Earnings ranged from a high of $15.6 billion in Q1 2026 to a low of $3.1 billion in Q3 2022.
• A 5-year average of $10.4 billion and a median of $10.6 billion in 2024 frame the typical range for Retained Earnings.
• Across the five-year window, Retained Earnings sank 71.53% in 2022 and surged 190.96% in 2023, its largest moves.
• Gsk's Retained Earnings stood at $5.1 billion in 2022, then soared by 75.57% to $9.0 billion in 2023, then increased by 11.37% to $10.0 billion in 2024, then soared by 35.71% to $13.6 billion in 2025, then gained by 13.26% to $15.4 billion in 2026.
• Per Business Quant data, the three most recent Retained Earnings figures were $15.4 billion in Q2 2026, $15.6 billion in Q1 2026, and $13.6 billion in Q4 2025.